Note: This study found no significant biological effects under its experimental conditions. We include all studies for scientific completeness.
Whole Body / General335 citations
Shen Y, Xia R, Jiang H, Chen Y, Hong L, Yu Y, Xu Z, Zeng Q
No Effects Found
Authors not listed · 2016
This bacterial surveillance study demonstrates the systematic long-term health monitoring that EMF research desperately needs.
Plain English Summary
Summary written for general audiences
This study tracked antibiotic resistance patterns in bacteria across Chinese hospitals from 2005 to 2014, analyzing over 20,000 to 84,000 bacterial samples annually. The research found mixed trends, with some bacteria becoming less resistant to certain antibiotics while others developed increased resistance to critical drugs like carbapenems. This surveillance work helps hospitals understand changing bacterial threats and guides treatment decisions.
Cite This Study
Unknown (2016). Shen Y, Xia R, Jiang H, Chen Y, Hong L, Yu Y, Xu Z, Zeng Q.
Show BibTeX
@article{shen_y_xia_r_jiang_h_chen_y_hong_l_yu_y_xu_z_zeng_q_ce4211,
author = {Unknown},
title = {Shen Y, Xia R, Jiang H, Chen Y, Hong L, Yu Y, Xu Z, Zeng Q},
year = {2016},
doi = {10.1016/j.cmi.2016.01.001},
}Quick Questions About This Study
CHINET is China's national bacterial surveillance network established in 2005 to track antibiotic resistance patterns across multiple hospitals. It uses standardized testing methods to monitor how bacteria respond to different antibiotics over time, helping identify emerging resistance threats.
The CHINET surveillance system analyzed between 22,774 and 84,572 bacterial isolates each year from 2005 to 2014. This large sample size allowed researchers to identify statistically significant trends in antibiotic resistance across different bacterial species.
Pseudomonas aeruginosa showed decreased resistance to all tested antibiotics, including critical drugs like imipenem and meropenem. Additionally, Staphylococcus aureus methicillin resistance dropped significantly from 69% in 2005 to 44.6% in 2014, representing a major improvement.
Carbapenem resistance increased dramatically in two key bacteria: Klebsiella pneumoniae resistance rose from 2.4% to 13.4%, while Acinetobacter baumannii carbapenem resistance jumped from 31% to 66.7%. These trends are particularly concerning because carbapenems are last-resort antibiotics.
Surveillance studies track disease patterns over time, enabling early detection of emerging health threats and informing treatment guidelines. This systematic monitoring approach helps healthcare systems respond effectively to changing bacterial resistance patterns and protect public health.